Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HLA-C_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HLA-C_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HLA-C_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HLA-C_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HLA-C_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HLA-C_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HLA-C_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HLA-C_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HLA-C_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HLA-C_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HLA-C_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HLA-C_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HLA-C_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00024839 | Breast | Precancer | antigen processing and presentation of endogenous peptide antigen | 8/1080 | 19/18723 | 5.10e-06 | 1.53e-04 | 8 |
GO:00198839 | Breast | Precancer | antigen processing and presentation of endogenous antigen | 9/1080 | 26/18723 | 8.75e-06 | 2.34e-04 | 9 |
GO:00480029 | Breast | Precancer | antigen processing and presentation of peptide antigen | 12/1080 | 62/18723 | 1.89e-04 | 3.04e-03 | 12 |
GO:00198859 | Breast | Precancer | antigen processing and presentation of endogenous peptide antigen via MHC class I | 6/1080 | 17/18723 | 2.59e-04 | 3.83e-03 | 6 |
GO:00024749 | Breast | Precancer | antigen processing and presentation of peptide antigen via MHC class I | 7/1080 | 28/18723 | 8.46e-04 | 9.82e-03 | 7 |
GO:004800213 | Breast | IDC | antigen processing and presentation of peptide antigen | 18/1434 | 62/18723 | 5.28e-07 | 2.59e-05 | 18 |
GO:000248314 | Breast | IDC | antigen processing and presentation of endogenous peptide antigen | 9/1434 | 19/18723 | 4.03e-06 | 1.43e-04 | 9 |
GO:001988313 | Breast | IDC | antigen processing and presentation of endogenous antigen | 10/1434 | 26/18723 | 1.14e-05 | 3.08e-04 | 10 |
GO:00198829 | Breast | IDC | antigen processing and presentation | 20/1434 | 106/18723 | 1.41e-04 | 2.49e-03 | 20 |
GO:001988513 | Breast | IDC | antigen processing and presentation of endogenous peptide antigen via MHC class I | 7/1434 | 17/18723 | 1.49e-04 | 2.61e-03 | 7 |
GO:000247412 | Breast | IDC | antigen processing and presentation of peptide antigen via MHC class I | 8/1434 | 28/18723 | 9.00e-04 | 1.04e-02 | 8 |
GO:004800222 | Breast | DCIS | antigen processing and presentation of peptide antigen | 20/1390 | 62/18723 | 1.01e-08 | 7.56e-07 | 20 |
GO:000248323 | Breast | DCIS | antigen processing and presentation of endogenous peptide antigen | 9/1390 | 19/18723 | 3.11e-06 | 1.02e-04 | 9 |
GO:001988323 | Breast | DCIS | antigen processing and presentation of endogenous antigen | 10/1390 | 26/18723 | 8.68e-06 | 2.37e-04 | 10 |
GO:001988214 | Breast | DCIS | antigen processing and presentation | 22/1390 | 106/18723 | 8.76e-06 | 2.38e-04 | 22 |
GO:001988523 | Breast | DCIS | antigen processing and presentation of endogenous peptide antigen via MHC class I | 7/1390 | 17/18723 | 1.23e-04 | 2.12e-03 | 7 |
GO:000247422 | Breast | DCIS | antigen processing and presentation of peptide antigen via MHC class I | 9/1390 | 28/18723 | 1.26e-04 | 2.18e-03 | 9 |
GO:004800210 | Cervix | CC | antigen processing and presentation of peptide antigen | 24/2311 | 62/18723 | 1.21e-07 | 6.07e-06 | 24 |
GO:001988210 | Cervix | CC | antigen processing and presentation | 32/2311 | 106/18723 | 8.61e-07 | 3.08e-05 | 32 |
GO:000248310 | Cervix | CC | antigen processing and presentation of endogenous peptide antigen | 11/2311 | 19/18723 | 2.89e-06 | 8.23e-05 | 11 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0533011 | Lung | MIAC | Allograft rejection | 7/507 | 38/8465 | 6.61e-03 | 4.27e-02 | 3.09e-02 | 7 |
hsa0516671 | Lung | MIAC | Human T-cell leukemia virus 1 infection | 23/507 | 222/8465 | 7.02e-03 | 4.44e-02 | 3.21e-02 | 23 |
hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa0516928 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
hsa0421820 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
hsa051659 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa0516729 | Oral cavity | OSCC | Kaposi sarcoma-associated herpesvirus infection | 125/3704 | 194/8465 | 3.67e-09 | 3.84e-08 | 1.96e-08 | 125 |
hsa0517027 | Oral cavity | OSCC | Human immunodeficiency virus 1 infection | 133/3704 | 212/8465 | 1.42e-08 | 1.40e-07 | 7.12e-08 | 133 |
hsa0516328 | Oral cavity | OSCC | Human cytomegalovirus infection | 139/3704 | 225/8465 | 2.77e-08 | 2.38e-07 | 1.21e-07 | 139 |
hsa052038 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
hsa0414528 | Oral cavity | OSCC | Phagosome | 88/3704 | 152/8465 | 2.83e-04 | 9.13e-04 | 4.65e-04 | 88 |
hsa0541629 | Oral cavity | OSCC | Viral myocarditis | 39/3704 | 60/8465 | 7.13e-04 | 2.09e-03 | 1.07e-03 | 39 |
hsa0461229 | Oral cavity | OSCC | Antigen processing and presentation | 47/3704 | 78/8465 | 2.37e-03 | 6.35e-03 | 3.23e-03 | 47 |
hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
hsa05169113 | Oral cavity | OSCC | Epstein-Barr virus infection | 144/3704 | 202/8465 | 1.08e-15 | 3.60e-14 | 1.83e-14 | 144 |
hsa05166113 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
hsa04218110 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
hsa0516514 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa05167113 | Oral cavity | OSCC | Kaposi sarcoma-associated herpesvirus infection | 125/3704 | 194/8465 | 3.67e-09 | 3.84e-08 | 1.96e-08 | 125 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HLA-C | SNV | Missense_Mutation | | c.575N>G | p.Leu192Arg | p.L192R | P10321 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
HLA-C | SNV | Missense_Mutation | novel | c.1008N>C | p.Lys336Asn | p.K336N | P10321 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.992) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-C | SNV | Missense_Mutation | | c.376N>C | p.Asp126His | p.D126H | P10321 | protein_coding | deleterious_low_confidence(0.01) | benign(0.028) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HLA-C | SNV | Missense_Mutation | novel | c.493C>G | p.Gln165Glu | p.Q165E | P10321 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.984) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-C | SNV | Missense_Mutation | rs11547351 | c.296G>C | p.Arg99Pro | p.R99P | P10321 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.98) | TCGA-VS-A9UR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
HLA-C | SNV | Missense_Mutation | novel | c.349N>G | p.His117Asp | p.H117D | P10321 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-ZJ-AAXT-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
HLA-C | SNV | Missense_Mutation | | c.425A>C | p.Tyr142Ser | p.Y142S | P10321 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HLA-C | SNV | Missense_Mutation | | c.773N>T | p.Arg258Met | p.R258M | P10321 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HLA-C | SNV | Missense_Mutation | rs281860353 | c.170N>C | p.Phe57Ser | p.F57S | P10321 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-C | SNV | Missense_Mutation | rs281860449 | c.367N>C | p.Ser123Pro | p.S123P | P10321 | protein_coding | deleterious_low_confidence(0.01) | benign(0.174) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | flucloxacillin | FLOXACILLIN | 30664875 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | peginterferon alfa-2b | | |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | THERAPEUTIC TUMOR INFILTRATING LYMPHOCYTES | | 27959684 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | clavulanate | CLAVULANIC ACID | 30664875 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | amoxicillin | AMOXICILLIN | 30664875 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | Drugs For Treatment Of Tuberculosis | | 23153709 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | methotrexate | METHOTREXATE | 28444425 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | ribavirin | RIBAVIRIN | |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | ustekinumab | USTEKINUMAB | 23521149 |
3107 | HLA-C | CELL SURFACE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | clozapine | CLOZAPINE | 11266078 |